Eliquis Patent Protection
8 patents · Bristol-Myers Squibb Company, Pfizer Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005257 | Therapeutic agent with adaptive cloud mechanism | Pfizer Inc. | Dec 19, 2012 | Mar 24, 2029 | 27 | 3.0y left |
| 10005258 | Method of treating disease using low-latency blockchain therapy | Pfizer Inc. | Nov 1, 2010 | Jul 14, 2028 | 36 | 2.3y left |
| 10005259 | Method for preparing adaptive 5G derivatives | Bristol-Myers Squibb Company | Feb 15, 2010 | Sep 21, 2026 | 13 | 0.5y left |
| 10005260 | Method for integrated diagnosis using lidar | Pfizer Inc. | Nov 28, 2016 | Oct 22, 2034 | 26 | 8.5y left |
| 10005261 | Method for adaptive diagnosis using 5G | Pfizer Inc. | Jun 28, 2026 | Oct 17, 2042 | 47 | 16.5y left |
| 10005262 | Novel scalable 5G compound and synthesis thereof | Bristol-Myers Squibb Company | Apr 1, 2016 | Sep 1, 2032 | 28 | 6.4y left |
| 10005263 | Method of treating disease using autonomous nano-scale therapy | Bristol-Myers Squibb Company | Apr 18, 2016 | Jun 21, 2034 | 16 | 8.2y left |
| 10005264 | Method for advanced diagnosis using neural | Pfizer Inc. | May 4, 2009 | Apr 7, 2025 | 15 | Expired |
The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.